Nuclear Imaging and Radiotherapeutics Agents Targeting Carbonic Anhydrase IX

Case ID:
C13559
Disclosure Date:
4/21/2015
Description:
Unmet Need
During early stages of tumorigenesis, rapidly differentiating tumor cells create regions of hypoxic activity where metabolic demands surpass the local vascular oxygen supply. The lactic acid generated from the resulting hypoxia can trigger expression of carbonic anhydrase IX (CA IX), a gene responsible for pH maintenance that provides a mechanism for the rapidly expanding tumor to survive the local toxic region. The onset of tumor acidosis, a corresponding low pH, and upregulation of CA IX are all important biomarkers of the acceleration of tumor progression. This progression of CA IX is present in many organ specific cancers, including breast, lung, gastric, ovarian, and colon malignancies. Radiotracer and radiotherapeutic agents designed to target and deliver treatment to the CA IX sites can provide a precise entry point to stop tumor progression.
 
Technology Overview
Researchers in the Johns Hopkins School of Medicine Department of Radiology and Radiological Science have created highly potent and selective low-molecular-weight (LMW) ligands of CA IX with a dual-targeting moiety. These compounds were conjugated with metal chelators, metal complexes, and fluorine prosthetic groups. This discovery enables radio-labeling with a wide array of PET, SPECT and radiotherapeutic isotopes.
 
Stage of Development
The inventors have conducted animal model studies using mice bearing CA IX+ tumors (SK-RC-52). Preliminary results show that injected tracers provided successful imaging of the tumors with minimum non-target organ uptake. Radioisotope labeled CA IX targeting agents stand to enable a wide range of imaging and therapeutic applications, including but not limited to renal cell carcinoma.
 
Publications
Minn I, et al. Oncotarget. 2016 Aug 30;7(35):56471-56479.
 
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Nuclear Imaging and Radiotherapeutics Agents Targeting Carbonic Anhydrase IX PCT: Patent Cooperation Treaty PCT PCT/US2016/035259   6/1/2016     Expired
Nuclear Imaging and Radiotherapeutics Agents Targeting Carbonic Anhydrase IX PCT: Patent Cooperation Treaty United States 15/578,473 6/1/2016     Pending
Inventors:
Category(s):
For Information, Contact:
Jeanine Pennington
jpennin5@jhmi.edu
410-614-0300
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum